Drugs Made In America Acquisition II Corp. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Roger Bendelac (CEO) and Saleem Elmasri (CFO) filed standard Sarbanes-Oxley certifications on August 14, 2026 for the quarterly period ended June 30, 2026. Both officers certify the 10-Q filing complies with SEC requirements, financial statements fairly present the company's condition, and internal controls are functioning. No material weaknesses, deficiencies, or fraud are disclosed.
Why this rating
Routine SOX 302/906 certification exhibits; boilerplate officer attestations with no disclosed control issues, errors, or business events.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.